Artiva Biotherapeutics, Inc. ARTV Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $69.54M+38.2% | $50.33M+0.2% | ||
| $20.27M+17.8% | $17.21M+23.7% | ||
| $89.81M+33.0% | $67.54M+5.3% | ||
| -$89.81M-33.5% | -$67.28M-119% | ||
| $5.95M+211% | $1.91M-5.5% | ||
| -$83.87M-28.3% | -$65.37M-128% | ||
| -$3.42— | —— | ||
| -$87.21M-34.5% | -$64.85M— | ||
| -$89.81M-33.5% | -$67.28M-119% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Artiva Biotherapeutics, Inc. profitable?
- Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.
- What is Artiva Biotherapeutics, Inc.'s earnings per share?
- Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.
- Where does Artiva Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.